GlobeNewsWire
24 Oct 2025, 14:00 UTC · 47w ago
Verdict
Headline takes no side. We score MRUS +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Petosemtamab in combination with standard of care achieved a 100% response rate in first-line left-sided metastatic colorectal cancer (n=8).
So whatA 100% response rate in any oncology cohort, even a small one, is an exceptionally strong clinical signal that substantially de-risks the drug's commercial potential and boosts the developer's valuation.
More positive than 99% of claims this week
Petosemtamab in combination with standard of care achieved a 62% response rate in second-line left- and right-sided metastatic colorectal cancer (n=13).
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 97% of claims this week
The interim data demonstrate that petosemtamab can be safely combined with standard-of-care chemotherapy FOLFOX/FOLFIRI.
More positive than 97% of claims this week
The interim data indicate clinical activity for petosemtamab beyond its original focus in head and neck squamous cell carcinoma.
So whatExpanding the drug's potential addressable market into a new major solid tumor type materially increases the peak revenue estimate for the asset.
More positive than 85% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company reported highly positive interim phase 2 clinical data, including a 100% response rate in 1L left-sided mCRC.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Market Watch
6h ago
−4.7%
Price is moving against the score
$90.00 vs $94.42 close before publication (Oct 23) · not market-adjusted
MRUS chart →
